.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Teva
Queensland Health
Express Scripts
Federal Trade Commission
Harvard Business School
Deloitte
Baxter
Medtronic
US Army

Generated: November 21, 2017

DrugPatentWatch Database Preview

VELTASSA Drug Profile

« Back to Dashboard

What is the patent landscape for Veltassa, and when can generic versions of Veltassa launch?

Veltassa is a drug marketed by Relypsa Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has one hundred and thirty-one patent family members in twenty-one countries.

The generic ingredient in VELTASSA is patiromer sorbitex calcium. One supplier is listed for this compound. Additional details are available on the patiromer sorbitex calcium profile page.

Summary for VELTASSA

US Patents:10
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 9
Drug Prices:see details
DailyMed Link:VELTASSA at DailyMed

Pharmacology for VELTASSA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-003Oct 21, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-003Oct 21, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-003Oct 21, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-003Oct 21, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-001Oct 21, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-002Oct 21, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-003Oct 21, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-001Oct 21, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-001Oct 21, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-002Oct 21, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VELTASSA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,429,394Ion binding compositions► Subscribe
7,854,924Methods and compositions for treatment of ion imbalances► Subscribe
8,192,758Ion binding compositions► Subscribe
8,445,014Ion binding compositions► Subscribe
8,409,561Methods and compositions for treatment of ion imbalances► Subscribe
8,282,960Ion binding compositions► Subscribe
7,776,319Methods and compositions for treatment of ion imbalances► Subscribe
7,488,495Ion binding polymers and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VELTASSA

Country Document Number Estimated Expiration
South Korea20120130255► Subscribe
Japan2007531774► Subscribe
United Kingdom2495427► Subscribe
South Korea101199608► Subscribe
China104822383► Subscribe
Germany112009002063► Subscribe
Spain2338667► Subscribe
Spain2453048► Subscribe
European Patent Office2269589► Subscribe
South Korea20120060920► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Covington
UBS
Dow
Fish and Richardson
QuintilesIMS
Daiichi Sankyo
Farmers Insurance
McKesson
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot